GlassScriptPhysician profile
Nima Ghasemzadeh
NPI 1154564367
$6,655.28
in general payments reported to CMS, 2019-2025
40 companies · $518 in 2025
The $518 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $1,070 · 2021: $1,287 · 2022: $1,126 · 2023: $980 · 2024: $655 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,705.44 | 2019-2025 | Optis, Xience Skypoint, Coroflow |
| Boston Scientific Corporation | $694.78 | 2019-2025 | General - Balloon Catheters, Avvigo Guidance System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $551.04 | 2019-2025 | Lifevest |
| Medtronic, INC. | $525.40 | 2021-2024 | Onyx Frontier |
| Philips North America LLC | $524.28 | 2022 | |
| Shockwave Medical, INC | $328.71 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Novartis Pharmaceuticals Corporation | $273.69 | 2019-2024 | |
| Pfizer INC. | $230.65 | 2019-2025 | |
| Edwards Lifesciences Corporation | $186.98 | 2019-2022 | |
| Medtronic Vascular, INC. | $166.43 | 2019-2020 | |
| Terumo Medical Corporation | $144.45 | 2022 | |
| Cardiovascular Systems INC. | $138.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $126.73 | 2019-2024 | Xarelto |
| Janssen Research & Development, LLC | $120.00 | 2023 | |
| Abiomed | $115.92 | 2024-2025 | Impella |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112.25 | 2019-2023 | Repatha |
| Angiodynamics, INC. | $89.10 | 2021-2023 | Angiovac |
| Inari Medical, INC. | $77.88 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $65.74 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $64.01 | 2019-2025 | Eliquis, Camzyos |
| Lexicon Pharmaceuticals, INC. | $61.86 | 2023-2024 | Inpefa |
| Cvrx, INC. | $39.31 | 2025 | Barostim Neo System |
| Livanova USA, INC. | $34.07 | 2022 | |
| Spectrawave, INC | $32.91 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Teleflex LLC | $25.00 | 2025 | Trapliner |
| Getinge USA Sales, LLC | $24.45 | 2022 | |
| Kestra Medical Technology Services, INC. | $23.02 | 2024 | Assure Wcd |
| Chiesi USA, INC. | $20.37 | 2019 | |
| Merit Medical Systems INC | $19.82 | 2025 | Prelude Introducers |
| Merck Sharp & Dohme LLC | $17.91 | 2023 | Verquvo |
| Heartflow, INC. | $17.60 | 2025 | |
| Cardiva Medical, INC. | $17.59 | 2022 | |
| Novo Nordisk INC | $17.49 | 2023 | |
| Esperion Therapeutics, INC. | $17.09 | 2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $16.73 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $14.56 | 2019 | |
| Penumbra, INC. | $13.95 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Ghasemzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.